Sahel Medical Journal

ORIGINAL ARTICLE
Year
: 2006  |  Volume : 9  |  Issue : 2  |  Page : 64--68

Lupus anticoagulant in adult sickle cell anaemia patients


E Olayemi1, NKD Halim2, MA Durosinmi3, 4 
1 Department of Haematology and Blood Transfusion, Obafemi Awolowo College of Health Sciences, Olabisi Onabanjo University, P.M.B. 2022, Sagamu, Ogun State, Nigeria
2 Department of Haematology and Blood Transfusion, University of Benin,Benin City, Edo State, Nigeria
3 Department of Haematology and Immunology, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria

Correspondence Address:
E Olayemi
Department of Haematology and Blood Transfusion, Obafemi Awolowo College of Health Sciences, Olabisi Onabanjo University, P.M.B. 2022, Sagamu, Ogun State
Nigeria

Background and Objectives: The lupus anticoagulant (LA) is an antiphosphollpid antibody (APLA), which prolongs phospholipid - dependent coagulation tests by interfering with coagulation reactions dependent on protein- phospholipid complexes in vitro. LA has been described in patients with beta-thalasaemia and children with SCD. This study was designed to determine the frequency of LA in adult SCA patients and if present in some patients to compare the frequency of crises, complications, blood transfusion, packed cell volume (PCV) and platelet count among SCA patients with LA and those without LA. Methodology: One hundred and forty nine SCA patients were screened for the presence of LA using the KCT. Kaolin clotting time index (KCTI) was calculated to determine the presence of LA; a ratio equal to or greater than 1.2 was taken to signify the presence of LA. Results: Seventeen patients had LA with KCTI >1.2, two of these had a prior history of transient ischemic attacks. Comparisons of the means of estimated number of bone pain crises per year, age at first complication of SCA, number of admissions in the previous year before the study and PCV In SCA patients with and without LA were not statistically significant. Conclusion: KCT provides a sensitive method to screen SCA patients for LA so that those with LA can be closely monitored and treatment offered where indicated.


How to cite this article:
Olayemi E, Halim N, Durosinmi M A,. Lupus anticoagulant in adult sickle cell anaemia patients.Sahel Med J 2006;9:64-68


How to cite this URL:
Olayemi E, Halim N, Durosinmi M A,. Lupus anticoagulant in adult sickle cell anaemia patients. Sahel Med J [serial online] 2006 [cited 2024 Mar 29 ];9:64-68
Available from: https://www.smjonline.org/article.asp?issn=1118-8561;year=2006;volume=9;issue=2;spage=64;epage=68;aulast=Olayemi;type=0